Febuxostat for the management of hyperuricaemia in people with gout - guidance (TA164)

National Institute for Health and Care Excellence - NICE
Publication date:
17 December 2008


Evidence-based recommendations on febuxostat (Adenuric) for managing hyperuricaemia in adults with gout.

Guidance development process

How we develop NICE technology appraisal guidance

Is this guidance up to date?

We reviewed the evidence in October 2016. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.